1 May 2008 in American Journal of Physiology-Lung Cellular and Molecular Physiology
SGSrinivasa R. Gangireddy
+3
Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this condition are largely ineffective. Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a member of the nuclear hormone receptor superfamily, the activation of which produces a number of biological effects, including alterations in metabolic and inflammatory responses. The role of PPAR-γ as a potential therapeutic target for fibrotic lung diseases remains undefined. In the present study, we show expression of PPAR-γ in fibroblasts obtained from normal human lungs and lungs of patients with idiopathic interstitial pneumonias. Treatment of lung fibroblasts and myofibroblasts with PPAR-γ agonists results in inhibition of proliferative responses and induces cell cycle arrest. In addition, PPAR-γ agonists, including a constitutively active PPAR-γ construct (VP16-PPAR-γ), inhibit the ability of transforming growth factor-β1 to induce myofibroblast differentiation and collagen secretion. PPAR-γ agonists also inhibit fibrosis in a murine model, even when administration is delayed until after the initial inflammation has largely resolved. These observations indicate that PPAR-γ is an important regulator of fibroblast/myofibroblast activation and suggest a role for PPAR-γ ligands as novel therapeutic agents for fibrotic lung diseases.
1 July 2010 in Journal of Biological Chemistry
MSMadathilparambil V. Suresh
Madathilparambil V. Suresh
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that play central roles in metabolism and inflammation. Although a variety of compounds have been shown to activate PPARs, identification of physiologically relevant ligands has proven difficult. In silico studies of lipid derivatives reported here identify specific 5-lipoxygenase products as candidate physiologically relevant PPAR-alpha activators. Subsequent studies show both in vitro and in a murine model of inflammation that 5-lipoxygenase stimulation induces PPAR-alpha signaling and that this results specifically from production of the inflammatory mediator and chemoattractant leukotriene B(4) (LTB(4)). Activation of PPAR-alpha is a direct effect of intracellularly generated LTB(4) binding to the nuclear receptor and not of secreted LTB(4) acting via its cell-surface receptors. Activation of PPAR-alpha reduces secretion of LTB(4) by stimulating degradation of this fatty acid derivative. We also show that the LTB(4) precursors leukotriene A(4) (LTA(4)) and 5-hydroperoxyeicosatetrenoic acid (5-HPETE) activate PPAR-alpha but have no significant endogenous effect independent of conversion to LTB(4). We conclude that LTB(4) is a physiologically relevant PPAR-alpha activator in cells of the immune system. This, together with previous findings, demonstrates that different types of lipids serve as endogenous PPAR-alpha ligands, with the relevant ligand varying between functionally different cell types. Our results also support the suggestion that regulation of inflammation may involve balancing proinflammatory effects of LTB(4), exerted through cell-surface receptors, and anti-inflammatory effects exerted through PPAR-alpha activation.
1 May 2010 in American Journal of Physiology-Lung Cellular and Molecular Physiology
SGSrinivasa R. Gangireddy
+2
Idiopathic pulmonary fibrosis (IPF) is a progressive and typically fatal lung disease for which no effective therapy has been identified. The disease is characterized by excessive collagen deposition, possibly in response to dysregulated wound healing. Mediators normally involved in would healing induce proliferation of fibroblasts and their differentiation to myofibroblasts that actively secrete collagen. Curcumin, a polyphenolic compound from turmeric, has been shown to exert a variety of biological effects. Effects on IPF and associated cell types remain unclear, however. We accordingly tested the ability of curcumin to inhibit proliferation and differentiation to myofibroblasts by human lung fibroblasts, including those from IPF patients. To further examine the potential usefulness of curcumin in IPF, we examined its ability to reduce fibrosis in bleomycin-treated mice. We show that curcumin effectively reduces profibrotic effects in both normal and IPF fibroblasts in vitro and that this reduction is accompanied by inhibition of key steps in the transforming growth factor-β (TGF-β) signaling pathway. In vivo, oral curcumin treatment showed no effect on important measures of bleomycin-induced injury in mice, whereas intraperitoneal curcumin administration effectively inhibited inflammation and collagen deposition along with a trend toward improved survival. Intraperitoneal curcumin reduced fibrotic progression even when administered after the acute bleomycin-induced inflammation had subsided. These results encourage further research on alternative formulations and routes of administration for this potentially attractive IPF therapy.
15 November 2008 in Blood
Neutrophils (polymorphonuclear leukocytes [PMNs]) are critical to the immune response, including clearance of infectious pathogens. Sepsis is associated with impaired PMN function, including chemotaxis. PMNs express peroxisome proliferator-activated receptor-γ (PPAR-γ), a ligand-activated nuclear transcription factor involved in immune and inflammatory regulation. The role of PPAR-γ in PMN responses, however, is not well characterized. We report that freshly isolated human PMNs constitutively express PPAR-γ, which is up-regulated by the sepsis-induced cytokines TNF-α and IL-4. PMN chemotactic responses to formylmethionyl-leucyl-phenylalanine (fMLP) and IL-8 were dose-dependently inhibited by treatment with the PPAR-γ ligands troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and by transfection of PMN-like HL-60 cells with a constitutively active PPAR-γ construct. Inhibition of chemotaxis by PPAR-γ ligands correlated with decreases in extracellular signal-regulated kinase-1 and -2 activation, actin polymerization, and adherence to a fibrinogen substrate. Furthermore, PMN expression of PPAR-γ was increased in sepsis patients and mice with either of 2 models of sepsis. Finally, treatment with the PPAR-γ antagonist GW9662 significantly reversed the inhibition of PMN chemotaxis and increased peritoneal PMN recruitment in murine sepsis. This study indicates that PPAR-γ activation is involved in PMN chemotactic responses in vitro and may play a role in the migration of these cells in vivo.
1 January 2010 in Current Opinion in Hematology
Neutrophil recruitment to sites of infection is a critical element of the innate immune response. In patients with sepsis, this response is dysregulated, with exuberant inflammation being followed by a state of profound immune suppression, including inhibition of neutrophil recruitment. This review examines mechanisms underlying suppression of neutrophil migration during sepsis. Mechanisms governing neutrophil chemotactic function in sepsis are complex. Bacterial products, cytokines, and chemokines can modulate neutrophil migratory responses during sepsis via induction of cytoskeletal changes, inhibition of polymorphonuclear leukocyte (PMN)–endothelial cell interactions, and alterations in G protein-coupled receptor expression or signaling. Impaired chemotactic responses can occur as a result of dysregulated PMN Toll-like receptor signaling. Other recently identified inhibitory mechanisms include exposure to elevated temperatures, activation of the anti-inflammatory nuclear transcription factor peroxisome proliferator-activated receptor-γ, and suppression of PMN–endothelial interactions due to nitric oxide and its metabolites. Finally, circulating microparticles released in sepsis exert important immunomodulatory effects on PMN adherence and transmigration. Neutrophil recruitment is a coordinated process that is altered at multiple stages during sepsis, culminating in defective innate immunity and increased risk of infection in these patients. Defining mechanisms involved and strategies to interrupt these deleterious responses requires further investigation.
1 March 2004 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Peroxisome proliferator-activated receptor-γ (PPAR-γ), a member of the nuclear hormone receptor family of ligand-dependent transcription factors, is a critical regulator of adipocyte differentiation and glucose metabolism. The expression, regulation, and functional significance of PPAR-γ in alveolar macrophages (AMs), the predominant resident immune effector cell within the alveolus, have not been previously examined. In this study, we show that, in contrast to peritoneal macrophages, resident murine AMs constitutively express high levels of PPAR-γ. Expression was primarily located in the nucleus by immunofluorescence staining. Quantitative real-time RT-PCR demonstrated that the predominant isoform was PPAR-γ2. Expression of PPAR-γ was induced by the anti-inflammatory cytokine IL-4. Treatment of murine AMs with PPAR-γ ligands suppresses PMA-stimulated oxidative burst activity and LPS + IFN-γ-mediated expression of inducible nitric oxide synthase. In addition, LPS-induced IL-12 mRNA and protein expression was inhibited by PPAR-γ ligands. These results support an important immunomodulatory role for PPAR-γ in AM responses.